Cargando…

Monitoring safety and effectiveness of Tafamidis in transthyretin amyloidosis in Italy: a 3-year longitudinal multicenter study in a non-endemic area

Detalles Bibliográficos
Autores principales:	Cortese, Andrea, Vita, Giuseppe, Obici, Laura, Sabatelli, Marco, Fabrizi, Gian Maria, Schenone, Angelo, Merlini, Giampaolo, Pareyson, Davide
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4642123/ http://dx.doi.org/10.1186/1750-1172-10-S1-P6

Ejemplares similares

Effects of Tafamidis on Transthyretin Stabilization and Clinical Outcomes in Patients with Non-Val30Met Transthyretin Amyloidosis
por: Merlini, Giampaolo, et al.
Publicado: (2013)

Psychosocial burden and professional and social support in patients with hereditary transthyretin amyloidosis (ATTRv) and their relatives in Italy
por: Magliano, Lorenza, et al.
Publicado: (2021)

Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis
por: Coelho, Teresa, et al.
Publicado: (2016)

Hereditary transthyretin amyloidosis overview
por: Manganelli, Fiore, et al.
Publicado: (2020)

Misdiagnoses of transthyretin amyloidosis: a clinical and electrodiagnostic study
por: Cortese, Andrea, et al.
Publicado: (2015)

A Review of Tafamidis for the Treatment of Transthyretin-Related Amyloidosis
por: Waddington Cruz, Márcia, et al.
Publicado: (2015)

Evaluation of Mortality During Long-Term Treatment with Tafamidis for Transthyretin Amyloidosis with Polyneuropathy: Clinical Trial Results up to 8.5 Years
por: Merlini, Giampaolo, et al.
Publicado: (2020)

Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis
por: Giblin, Gerard T, et al.
Publicado: (2022)

Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy
por: Cortese, Andrea, et al.
Publicado: (2017)

Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review
por: Cruz, Márcia Waddington
Publicado: (2019)

Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study
por: Damy, Thibaud, et al.
Publicado: (2020)

Magnetic resonance neurography and diffusion tensor imaging of the sciatic nerve in hereditary transthyretin amyloidosis polyneuropathy
por: Gasparotti, Roberto, et al.
Publicado: (2023)

Differential expression of Cathepsin E in transthyretin amyloidosis: from neuropathology to the immune system
por: Gonçalves, Nádia Pereira, et al.
Publicado: (2017)

Reverse cardiac remodelling and dysfunction in A97S transthyretin cardiac amyloidosis after tafamidis treatment
por: Wu, Yuan‐Kun (Aden), et al.
Publicado: (2022)

Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial
por: Li, Benjamin, et al.
Publicado: (2020)

Progressive brachial plexus enlargement in hereditary transthyretin amyloidosis
por: Salvalaggio, Alessandro, et al.
Publicado: (2021)

Prognostic Impact of the Increase in Cardiac Troponin Levels during Tafamidis Therapy in Patients with Transthyretin Cardiac Amyloidosis
por: Nakamura, Makiko, et al.
Publicado: (2023)

Recommendations for pre-symptomatic genetic testing for hereditary transthyretin amyloidosis in the era of effective therapy: a multicenter Italian consensus
por: Grandis, M., et al.
Publicado: (2020)

Tafamidis for a Transplant Patient with Transthyretin Amyloid Polyneuropathy
por: Romero-Imbroda, Jesús, et al.
Publicado: (2017)

Initial Experience With Tafamidis Treatment for Transthyretin Amyloid Cardiomyopathy
por: Nakamura, Makiko, et al.
Publicado: (2020)

Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis
por: Aimo, Alberto, et al.
Publicado: (2021)

Effect of Tafamidis on Serum Transthyretin Levels in Non-Trial Patients With Transthyretin Amyloid Cardiomyopathy
por: Falk, Rodney H., et al.
Publicado: (2021)

A Systematic Review of Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy
por: Singh, Bishnu Mohan, et al.
Publicado: (2021)

Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy
por: Elliott, Perry, et al.
Publicado: (2021)

Positive Effectiveness of Tafamidis in Delaying Disease Progression in Transthyretin Familial Amyloid Polyneuropathy up to 2 Years: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Mundayat, Rajiv, et al.
Publicado: (2018)

Therapeutic value of tafamidis in patients with wild-type transthyretin amyloidosis (ATTRwt) with cardiomyopathy based on cardiovascular magnetic resonance (CMR) imaging
por: Chamling, Bishwas, et al.
Publicado: (2022)

Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy
por: Coelho, Teresa, et al.
Publicado: (2013)

Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy
por: Sultan, Marla B, et al.
Publicado: (2017)

Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy
por: Rettl, René, et al.
Publicado: (2023)

Real‐life experience with inotersen in hereditary transthyretin amyloidosis with late‐onset phenotype: Data from an early‐access program in Italy
por: Luigetti, Marco, et al.
Publicado: (2022)

Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis
por: Coelho, Teresa, et al.
Publicado: (2019)

Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies
por: Rozenbaum, Mark H, et al.
Publicado: (2021)

Muscle quantitative MRI as a novel biomarker in hereditary transthyretin amyloidosis with polyneuropathy: a cross-sectional study
por: Vegezzi, Elisa, et al.
Publicado: (2022)

A study protocol for an observational cohort investigating cardiac transthyretin amyloidosis flow reserve before and after Tafamidis treatment: The AMYTRE study
por: Vançon, Bastien, et al.
Publicado: (2022)

Nerve ultrasound in hereditary transthyretin amyloidosis: red flags and possible progression biomarkers
por: Salvalaggio, Alessandro, et al.
Publicado: (2020)

Monitoring Tafamidis, The Most Expensive Cardiac Medication: Are Serum Transthyretin Levels the Answer?
por: Chang, Ian C., et al.
Publicado: (2021)

Burden of hereditary transthyretin amyloidosis on quality of life
por: Yarlas, Aaron, et al.
Publicado: (2019)

Guideline of transthyretin-related hereditary amyloidosis for clinicians
por: Ando, Yukio, et al.
Publicado: (2013)

Tafamidis decreased cardiac amyloidosis deposition in patients with Ala97Ser hereditary transthyretin cardiomyopathy: a 12-month follow-up cohort study
por: Tsai, Cheng-Hsuan, et al.
Publicado: (2023)

Reply to the letter regarding the article ‘Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study’
por: Damy, Thibaud, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8cqjfntcak1mb4gvceehc70uac